AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | Usana Health Sciences 2025 Half-Year Revenue USD 485.39 Million Net Income USD 19.73 Million
ByAinvest
Wednesday, Jul 23, 2025 12:00 am ET1min read
Usana Health Sciences(USNA) posted the Q2 of its 2025 financial results on 7/22/2025, reporting total revenue of USD 485.39 million in the first half of the year, up 10.15% from USD 440.67 million year over year, reporting net income of USD 19.73 million in the first half of the year, down 26.83% from USD 26.97 million year over year. The EPS is USD 1.0233 in the first half of the year, compare with USD 1.4156 last period.
[Detailed Data]
| Million USD | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Total Revenue | 235.85 | 249.54 | 213.61 | 200.22 |
| Cost of Sales | 50.18 | 52.45 | 38.55 | 39.26 |
| Gross Profit | 185.66 | 197.09 | 175.06 | 160.96 |
| Total Operating Expenses | 168.59 | 181.11 | 166.85 | 142.27 |
| Operating Income | 17.08 | 15.98 | 8.21 | 18.69 |
| Net Income | 10.44 | 9.29 | 4.48 | 10.61 |
| Net Income Attributable to Common Shareholders | 9.66 | 9.40 | 4.45 | 10.61 |
| EPS(USD) | 0.52 | 0.49 | 0.2337 | 0.56 |
[Company Profile]
Usana Health Sciences, Inc. was founded in 1992. The company is a global direct selling and direct-to-consumer nutrition, personal health and wellness company. In 2024, the company generated $855 million in net sales and finished the year with approximately 454,000 direct selling active Customers. The company was founded in 1992 by Myron W. Wentz, Ph.D. and since that time, the company has developed and manufactured high quality, science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness. The company is committed to continuous product innovation and sound scientific research. The company has operations in 25 geographic markets worldwide.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet